Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance)
- Citation:
- J Clin Oncol vol 32 (35) 3959-3966
- Year:
- 2014
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 4
- Parents:
- 444
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, CA33601, CA77597, CA11789, CA77406, CA16359, CA47577, CA35113, CA32291, CA29165, N01 CA032102, CA41287, CA03927, U10 CA031946, U10 CA033601, CA59518, U10 CA180821, CA45389, CA45808, N01 CA046441, CA86726, CA16450, CA77440, CA45564, U10 CA032102, CA74811, U10 CA180882, CA21060, U10 CA046441, CA47559, CA47642, CA45418, U10 CA180888, CA31983, CA31946
- Corr. Author:
- Authors:
- Harold J. Burstein Constance T. Cirrincione William T. Barry Helen K. Chew Sara M. Tolaney Diana E. Lake Cynthia Ma Kimberly L. Blackwell Eric P. Winer Clifford A. Hudis
- Networks:
- Study
- CALGB-40302
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Bc6, Bc7, ORIGINAL REPORTS, Breast Cancer